Rinvoq may be an option for patients who are unable to take, or did not benefit from, other treatment drugs for inflammatory conditions. This includes the TNF-alfa inhibitor Humira (via Drugs.com). As a JAK inhibitor, Rinvoq does have its differences and may potentially benefit patients who have yet to find symptom relief.

While both drugs are classified as antirheumatics, they do differ in terms of their number of drug interactions, dosage forms, half-life duration, and more. For example, Humira is reported to have a total of 475 known drug interactions. Rinvoq is reported to interact with 545 different medications. Additionally, Humira is taken in the form of an injection while Rinvoq is taken as an oral tablet. The two drugs also have differences in their half-life, or the amount of time it takes for drug levels in the body to reduce by half. For Humira, this takes 480 hours compared to the half-life of Rinvoq which is 14 hours.

Which medications may be best suited for a patient will always vary on a case-by-case basis and ultimately be determined by a healthcare professional based on many different factors.